NGL Fine Chem Ltd

NGLFINE

Watchlist

AI Mode

‌

Market Cap

₹ 893 Cr

P/E

43.17

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

OVERVALUED

Growth

SLUGGISH

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

NGL Fine-Chem Limited operates as a leading manufacturer of veterinary and human health APIs, offering high-quality products in both domestic and international markets.

In Q2FY26, revenue from operations surged to ₹120.26 crores, marking a notable 28.64% year-over-year growth fueled by strong demand across various regions.

The company is executing aggressive expansion plans, including brownfield and greenfield projects in Tarapur, poised to enhance capacity for regulated market penetration.

Management optimistically noted the first U.S. FDA API registration, marking a significant step towards entering lucrative U.S. markets alongside existing European regulatory compliance.

Despite the upbeat demand, the company remains cautiously optimistic, maintaining vigilance over sustaining the upturn and associated risks pertaining to pricing pressures and market dynamics.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

893 Cr

Volatility

Low Risk

P/E Ratio

43.2

Industry P/E

59.1

PEG Ratio

—

P/B Ratio

3.0

52W High

2,161.00

52W Low

962.70

Sales CAGR

8.73%

4.08%

18.75%

10Y

14.81%

Profit CAGR

-48.89%

-29.73%

11.33%

10Y

5.29%

ROE

TTM

6.89%

10.00%

16.33%

10Y

16.95%

ROCE

TTM

8.00%

13.07%

21.33%

10Y

22.45%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
FERMENTA	350.70	1,032 Cr	9.21	2.64	0.71	28.67	27.38	17.02
NGLFINE	1445.00	893 Cr	43.17	2.97	0.12	6.89	8.00	4.27
ANUHPHR	78.60	788 Cr	20.36	2.41	0.95	11.84	15.90	7.61
EVERESTO	483.05	469 Cr	70.87	6.46	0.00	9.12	9.87	2.79
INFINIUM	215.50	336 Cr	33.41	3.07	0.00	8.14	13.29	5.02
GENNEX	12.88	313 Cr	18.67	1.47	0.00	7.77	8.53	5.23
OXYGENTAPH	55.00	203 Cr	—	0.00	0.00	46.67	-53.26	-14.66

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	71	80	88	100	91	93	89	95	104	120
Expenses	61	66	74	84	81	82	84	89	93	103
Operating Profit	9.86	14	14	16	9.34	12	5.10	6.32	11	17
OPM %	13.88	17.42	15.76	15.86	10.29	12.37	5.72	6.65	10.54	14.27
Other Income	3.32	3.22	3.68	3.68	5.88	5.12	-0.13	-0.97	6.35	2.05
Interest	0.24	0.36	0.28	0.49	0.44	0.32	0.60	0.97	1.22	1.16
Depreciation	2.86	2.89	2.94	2.92	3.00	3.03	3.10	3.32	4.27	5.09
Profit Before Tax	10	14	14	16	12	13	1.27	1.06	12	13
Tax %	15.67	24.82	30.01	23.43	21.80	26.41	-0.79	49.06	21.96	25.77
Net Profit	8.51	10	10	12	9.22	9.81	1.28	0.54	9.24	9.63
EPS in Rs	13.77	16.96	16.24	19.95	14.92	15.88	2.07	0.88	14.96	15.58

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	153	152	258	318	278	339	368	382
Expenses	121	132	178	250	244	285	334	348
Operating Profit	32	19	80	68	34	53	34	34
OPM %	20.91	12.78	30.91	21.37	12.34	15.73	9.20	8.90
Other Income	4.12	3.05	8.02	11	5.53	14	8.63	10
Interest	2.29	2.26	1.84	1.56	1.20	1.34	2.33	3.11
Depreciation	6.30	8.11	8.33	10	11	12	12	14
Profit Before Tax	28	12	78	67	27	54	28	28
Tax %	26.99	30.96	26.90	25.08	25.09	24.07	23.78	24.11
Net Profit	20	8.34	57	50	20	41	21	21
EPS in Rs	32.80	13.71	91.85	80.70	33.99	66.92	33.75	33.49
Dividend Payout %	5.37	12.97	1.91	2.17	5.27	2.62	5.12	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	3.09	3.09	3.09	3.09	3.09	3.09	3.09
Reserves	89	96	151	200	219	260	279
Borrowings	23	23	11	27	30	32	73
Other Liabilities	27	32	42	47	34	60	78
Total Liabilities	142	154	207	277	287	356	433
Fixed Assets	61	68	64	89	88	86	143
CWIP	0.00	0.00	12	6.43	26	46	50
Investments	8.69	11	29	29	39	54	60
Other Assets	73	75	102	153	133	171	181
Total Assets	142	154	207	277	287	356	433

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	8.85	20	27	14	35	20	36
Cash from Investing Activity	-9.54	-20	-25	-14	-27	-27	-35
Cash from Financing Activity	0.00	-1.30	-1.08	-1.08	-1.08	-1.08	-1.08
Net Cash Flow	-0.70	-0.39	1.70	-1.46	7.18	-7.43	0.19

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	73.81%	73.53%	73.53%	73.06%	73.06%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%
FIIs	0.00%	0.00%	0.00%	0.02%	0.04%	0.10%	0.03%	0.02%	0.04%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	26.19%	26.47%	26.46%	26.92%	26.90%	27.16%	27.23%	27.25%	27.22%	27.26%	27.26%	27.26%
Total Shareholders	18,440	18,287	17,066	17,623	16,410	15,041	14,608	14,575	14,110	14,386	14,010	13,387

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Feb 20, 2024	Sunita potdar	Insider - Promoter Group	Disposal	1,995.46	3.99 Cr	20,000	0.32
Sep 16, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,008.39	0.13 Cr	636	0.01
Sep 14, 2023	Sunita potdar	Insider - Promoter Group	Disposal	1,998.40	0.00 Cr	10	0.00
Sep 14, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,008.39	0.10 Cr	474	0.00
Sep 13, 2023	Sunita potdar	Insider - Promoter Group	Disposal	1,998.75	0.84 Cr	4,191	0.06
Sep 09, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,014.01	0.97 Cr	4,823	0.07
Sep 08, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,100.60	0.26 Cr	1,256	0.02
Sep 06, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,122.29	1.98 Cr	9,348	0.15
Sep 05, 2023	Sunita potdar	Insider - Promoter Group	Disposal	2,228.72	1.92 Cr	8,600	0.13
Mar 21, 2023	Sunita potdar	Insider - Promoter Group	Disposal	1,251.91	0.01 Cr	110	0.00

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q4 FY24

Showing 1 - 8 of 21

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

NGL Fine-Chem Limited operates as a leading manufacturer of veterinary and human health APIs, offering high-quality products in both domestic and international markets.

In Q2FY26, revenue from operations surged to ₹120.26 crores, marking a notable 28.64% year-over-year growth fueled by strong demand across various regions.

The company is executing aggressive expansion plans, including brownfield and greenfield projects in Tarapur, poised to enhance capacity for regulated market penetration.

Management optimistically noted the first U.S. FDA API registration, marking a significant step towards entering lucrative U.S. markets alongside existing European regulatory compliance.

Despite the upbeat demand, the company remains cautiously optimistic, maintaining vigilance over sustaining the upturn and associated risks pertaining to pricing pressures and market dynamics.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs

Market Cap

893 Cr

Volatility

Low Risk

P/E Ratio

43.2

Industry P/E

59.1

PEG Ratio

—

P/B Ratio

3.0

52W High

2,161.00

52W Low

962.70

Sales CAGR

8.73%

4.08%

18.75%

10Y

14.81%

Profit CAGR

-48.89%

-29.73%

11.33%

10Y

5.29%

ROE

TTM

6.89%

10.00%

16.33%

10Y

16.95%

ROCE

TTM

8.00%

13.07%

21.33%

10Y

22.45%

Nglfine

NGL Fine Chem Ltd

NGLFINE

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Forecasts

Projection

NGL Fine Chem Ltd

NGLFINE

AI Mode

Announcements

Peers

Price Chart Comparison

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist